OSR Health (OSRHW) Cash from Investing Activities (2023 - 2026)
OSR Health (OSRHW) posted Cash from Investing Activities of $11677.5 for Q1 2026, up 100.45% sequentially from -$2.6 million in Q4 2025, and down 99.02% YoY from $1.2 million in Q1 2025.
OSR Health (OSRHW) Cash from Investing Activities (2023 - 2026) Analysis & Trends
OSR Health has reported Cash from Investing Activities for 4 years, with the latest figure at $11677.5 in Q1 2026.
- Quarterly Cash from Investing Activities fell 99.02% year-over-year to $11677.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.8 million (down 360.97% YoY) and the FY2025 annual result came in at -$2.6 million, down 624.81% from the prior year.
- Cash from Investing Activities advanced to $11677.5 in Q1 2026 per OSRHW's latest filing, from -$2.6 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $36.4 million in Q4 2023 and troughed at -$70.2 million in Q1 2023.
- A 4-year average of -$3.3 million and a median of $11677.5 in 2026 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 423.14% in 2025, down 1270.27% in 2025.
- Over 4 years, Cash from Investing Activities stood at $36.4 million in 2023, then sank by 100.52% to -$187812.0 in 2024, then sank by 1270.27% to -$2.6 million in 2025, then surged by 100.45% to $11677.5 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $11677.5, -$2.6 million, and -$726632.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | -229.72 Mn |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | 24.51 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | -88,325.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,677.48 |
| Mar 31, 2026 | 11,677.48 |
| Dec 31, 2025 | -2.57 Mn |
| Dec 31, 2025 | -2.57 Mn |
| Sep 30, 2025 | -726,632.00 |
| Sep 30, 2025 | -726,632.00 |
| Jun 30, 2025 | -528,423.52 |
| Jun 30, 2025 | -528,423.52 |
| Mar 31, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | -187,812.00 |
| Dec 31, 2024 | -187,812.00 |
| Sep 30, 2024 | 245,231.00 |
| Sep 30, 2024 | 245,231.00 |
| Jun 30, 2024 | 219,561.00 |
| Jun 30, 2024 | 219,561.00 |
| Mar 31, 2024 | 226,631.00 |
| Mar 31, 2024 | 226,631.00 |
| Dec 31, 2023 | 36.38 Mn |
| Dec 31, 2023 | 36.38 Mn |